A draft executive order obtained by The New York Times purports to clamp down on the pharmaceutical industry’s ability to buy new molecules from biotechs based in China, along with a number of other proposed reforms.
Trump Reportedly Preparing Order Restricting Chinese Drug Licensing Deals Read More »
The nonprofit giant plans to step into northern Nevada next year by partnering with regional system Renown. The deal includes a majority investment in Renown’s health plan, though financial terms were not disclosed.
Kaiser Permanente to expand into Nevada through joint venture with Renown Health Read More »
Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of epilepsy.
Capsida Reports Patient Death in Gene Therapy Trial Read More »
New York City has seen increased life sciences employment during the past decade as public funding and key projects like JLABS @ NYC have given the area a boost. A Partnership Fund for New York City executive discusses the city’s strengths and a notable challenge facing businesses.
New York City’s Life Sciences Scene Grows in Stature Read More »
The influential senator argued the technology giant delivered “dangerous, insecure software” to the health system that contributed to a massive cyberattack last year.
Wyden urges FTC to investigate Microsoft over Ascension cyberattack Read More »
Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a “smooth” approval process for Avidity’s del-zota.
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA Read More »
New draft guidelines suggest the FDA is open to exercising regulatory flexibility for non-opioid drugs being developed for chronic pain.
FDA Looks to Streamline Development of Non-Opioid Painkillers Read More »
Claiming that the domestic market undervalues pharma innovation, Merck has decided to pull the plug on all of its R&D efforts in the U.K.
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees Read More »
La empresa moderna pide foco. Pide velocidad. Pide sistemas que no fallen. Soft2Bet responde con una plataforma firme y dúctil. La base es clara. Tecnología que encaja. Operativa que fluye. Resultados que se miden. Aquí verás cómo su propuesta eleva el rendimiento …
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This webinar will show leaders how strategic insights and targeted outreach can turn awareness into high-converting leads. Watch now.
